Clinical effect of Pabolizumab on cutaneous malignant melanoma
YAO Yuchi1 WU Min2▲
1.Department of Burn and Plastic Surgery, Huai’an First Hospital Affiliated to Nanjing Medical University, Jiangsu Province, Huaian 223300, China; 2.Department of Oncology, Huai’an First Hospital Affiliated to Nanjing Medical University, Jiangsu Province, Huaian 223300, China
Abstract：Objective To explore the clinical effect of Pabolizumab in the treatment of cutaneous malignant melanoma. Methods A total of 64 patients with cutaneous malignant melanoma admitted to the Huai’an First Affiliated Hospital of Nanjing Medical University from March 2019 to January 2021 were selected as the research objects, and they were divided into study group and control group by random number table method, with 32 cases in each group. The control group was treated with surgery combined with chemotherapy, and the study group was treated with Pabolizumab on the basis of the control group. After four months of treatment, the clinical efficacy, quality of life, and adverse reactions of the two groups were evaluated, and the 1-year was recorded by follow-up. Results The disease control rate of the study group was higher than that of the control group, and the difference was statistically significant (P＜0.05); there was no significant difference in clinical remission rate between the two groups (P＞0.05). After treatment, the scores of social function, psychological function, and physical function of the two groups were higher than those before treatment, and the study group was higher than the control group (P＜0.05). The total incidence of adverse reactions in the study group was higher than that in the control group (P＜0.05). The survival curve of the study group was higher than that of the control group (P＜0.05). Conclusion Pabolizumab can significantly improve the disease control rate in the treatment of cutaneous malignant melanoma. There may be adverse reactions such as abnormal thyroid function， but the patients can tolerate it.
京公网安备 11010502046598号